UPMC Vision Institute

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Macular degeneration1 trial
• Retinitis pigmentosa1 trial

Phase

• Phase 11 trial
• Phase 1/21 trial
• Phase 31 trial

Status

• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• Ray Therapeutics, Inc.2 trials
• Alkeus Pharmaceuticals, Inc.1 trial

Running trials

• Recruiting

  Study of ALK-001 on the Progression of Stargardt Disease

  NCT07419334· Phase 3· Alkeus Pharmaceuticals, Inc.· Source

  Contact: Study Coordinator

• Recruiting

  Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

  NCT07439887· Phase 1/2· Ray Therapeutics, Inc.· Source

  Contact: UPMC Vision Institute Clinical Trials Team

• Active, not recruiting

  Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)

  NCT06460844· Phase 1· Ray Therapeutics, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration1 recruiting